Orserdu combinations show favorable safety profiles for ER+, HER2- metastatic breast cancer in phase Ib/II trials

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Menarini Group and Stemline Therapeutics Inc., a wholly-owned subsidiary of the Menarini Group, will present updated results from phase Ib/II ELECTRA and ELEVATE clinical studies evaluating elacestrant (Orserdu) in combination with other treatments at the 2024 American Society of Clinical Oncology on June 2. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Primary results from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz), a humanized monoclonal antibody targeting programmed death receptor-1, in combination with carboplatin and paclitaxel (platinum-based chemotherapy) in adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal cancer who have not been previously treated with systemic chemotherapy, were published in The Lancet. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login